Browse by category

Novo Nordisk files for FDA approval for CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues

Novo Nordisk has submitted a New Drug Application (NDA) to the FDA for once-weekly CagriSema (cagrilintide 2.4 mg and semaglutide 2.4 mg) injection, to be used with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity or overweight in the presence of at least one weight-related comorbid condition. CagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide 2

Novo Nordisk files for FDA approval for CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues

3 hours ago

Prescription drug monitoring needed post-MBS

2 days ago

Abdominal obesity and muscle loss increases the risk of death by 83% after age 50

4 days ago

Browse by category

Novo Nordisk files for FDA approval for CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues

Browse by tag

Novo Nordisk files for FDA approval for CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues

Prescription drug monitoring needed post-MBS

Abdominal obesity and muscle loss increases the risk of death by 83% after age 50

Back to Top